Lupin launches generic Liraglutide Injection in the U.S. market
New launch offers bioequivalent alternative to Victoza for type 2 diabetes management in adults and children aged 10 and above
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
FDA launches pilot program to prioritise review of U.S. made generic drug applications
New initiative offers faster ANDA reviews for companies using domestic manufacturing and testing to bolster U.S. pharma supply…
IPA announces leadership transition
Sharvil Patel, MD, Zydus Lifesciences and former VP, IPA, assumes the role of President,; Glenn Saldanha, Chairman and MD,…
Supriya Lifescience receives WHO GMP Certification for Ambernath Facility
Approval enables commercial production of formulations with projected revenue potential of ₹500 crore
AI compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging AI across nearly every aspect…
Understanding real-world microbiological outcomes will guide long-term CFTR modulator use in CF:…
Real-world microbiological data reveal complex trends in CFTR modulator therapy, highlighting the need for tailored long-term…
Driving India’s innovation edge
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma…
Parexel partners with Weave Bio to accelerate regulatory submission processes
Collaboration to focus on AI-driven regulatory automation with Parexel as CRO design partner
Biocon Biologics clears path for U.S. launch of denosumab biosimilars Bosaya and Aukelso
Settlement with Amgen enables commercialisation of Bosaya and Aukelso in the United States from October 1, 2025
Pfizer signs agreement with Trump Administration to lower U.S. drug prices and boost…
The agreement covers drug pricing parity, patient discounts through TrumpRx.gov, and a $70 billion U.S. investment commitment
Lupin receives US FDA approval for Rivaroxaban for oral suspension
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug…
Innovation has been at the heart of our growth journey
Sekhar Surabhi, CEO & Founder, Caliber Technologies and Director, ISPE India Affiliate, Chair, ISPE Pharma 4.0, Community of…
Saroj G. Warke receives “Women Empowerment Principles Leadership 2025” Award
Saroj G. Warke, Co-founder and IT Director of HiMedia Laboratories has received the prestigious “Women Empowerment Principles…
Inaugural edition of PCG 2025 marks milestone in India’s pharma innovation journey
The inaugural edition of the Peptides & Complex Generics Symposium (PCG 2025), jointly organised by the Mumbai Biocluster and…
CDSCO clarifies regulatory pathway for combi-pack approvals of Lyophilized injections &…
The Central Drugs Standard Control Organization (CDSCO) has issued a clarification concerning the regulatory approval process for…
Novo Nordisk to launch Ozempic in India, sets stage for GLP-1 market expansion
With semaglutide patents set to expire in 2026, Indian drugmakers are preparing to enter the market with generics. This…
Ayush Ministry inaugurates first integrative oncology research and care centre at AIIA Goa
The Ministry of Ayush inaugurated the Integrative Oncology Research and Care Centre (IORCC) at the All India Institute of Ayurveda…
Lupin acquires VISUfarma to strengthen ophthalmology business
Lupin’s wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition of VISUfarma B.V.…
Turning the tariff tight spot into a sweet spot
US President Trump's fresh salvo of 100 per cent tariffs on branded or patented pharmaceutical products not ‘Made in America’…
Pharma tariff bombshell: Navigating challenges, building resilience
Chakravarthi AVPS, International Trade & Business Relations Expert in pharmaceuticals, opines that for India Pharma Inc, the…